Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers

Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers

Source: 
Motley Fool
snippet: 

What's the next massive multibillion-dollar market for the biopharmaceutical industry? Put an increasingly prevalent liver disease high on the list.

Some analysts predict that the market for treatments of nonalcoholic steatohepatitis (NASH) could be between $20 billion and $35 billion.